Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory disease of the central nervous system that affects more than 2.3 million people worldwide. Over the past several years, the scientific advances in the pathophysiology and therapeutic options of MS have undergone tremendous expansion. It is critical for health care providers to be up-to-date with the most recent developments in the understanding of this disease, as well as its diagnosis and treatment approaches. In this CME program, leading experts will review various aspects of MS, including the advancements in imaging and biomarkers to diagnose the disease and monitor its progression. In addition, new therapeutic targets, symptomatic management, treatment during pregnancy, as well as the mechanisms of action, safety, and efficacy of established and emerging therapies, will also be discussed.
Multiple sclerosis (MS) and neuromyelitis optica (NMO) are both demyelinating disorders. Misdiagnosis has been common because many symptoms relating to these 2 disorders overlap. Differential diagnosis has important clinical implications because MS and NMO respond to different treatments. This case-based activity is designed to help clinicians distinguish between these 2 diseases and appropriately manage patients.
The expansion of the treatment landscape of multiple sclerosis (MS) over the past several years has increased the complexity of making treatment decisions. Clinicians face challenges with respect to choosing appropriate treatment regimens for individual patients. This activity will review the approved disease-modifying therapies to help clinicians navigate the current therapeutic landscape for MS.
Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory disease of the central nervous system that affects more than 2.3 million people worldwide. First-line treatments often fail to adequately control disease activity in patients with MS. This case-based activity is designed to help clinicians with the process of treatment optimization in patients with MS and with early switching to high-efficacy therapy with breakthrough disease activity.
Multiple sclerosis (MS) predominantly affects women of childbearing age; thus, the issues of conception and pregnancy have become of significant importance to physicians and patients. Clinicians must be prepared to counsel patients and discuss the risks, as well as the benefits, of treatment during pregnancy. This activity will review the effects of MS on pregnancy, as well as the management of MS during the prepregnancy, pregnancy, and postpartum periods.
The past several decades have seen tremendous progress in the treatment of relapsing-remitting multiple sclerosis (MS). In contrast, the treatment of progressive MS remains challenging. Improved understanding of the underlying biology of disease progression has led to the identification of therapeutic targets and potential new treatments. This activity will summarize the clinical trial evidence on emerging therapies for progressive MS to help clinicians integrate these agents effectively into future treatment regimens.